Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
HOTH THERAPEUTICS, INC.
(Name of Issuer)
Common stock, par value $0.0001 per share
(Title of Class of Securities)
44148G105
(CUSIP Number)
May 26, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| þ | Rule 13d-1(c) |
| ☐ | Rule 13d-1(d) |
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 44148G105
| 1. |
Names of Reporting Persons
AIkido Pharma, Inc. | |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) þ | |
| 3. | SEC Use Only
| |
| 4. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned By Each Reporting Person With: |
5. | Sole Voting Power
1,130,674 | ||
| 6. | Shared Voting Power
0 | |||
| 7. | Sole Dispositive Power
1,130,674 | |||
| 8. | Shared Dispositive Power
0 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
1,130,674 | |
| 10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
| |
| 11. |
Percent of Class Represented by Amount in Row (9)
9.74%(1) | |
| 12. |
Type of Reporting Person (See Instructions)
CO |
| (1) | This percent is based on the 11,601,707 common shares issued and outstanding by Hoth Therapeutics, Inc. as of May 20, 2020, and the 1,130,670 shares directly, beneficially owned by AIkido Pharma, Inc. following their sale of 400,000 shares on May 26, 2020. |
2
| Item 1(a). | Name of Issuer |
Hoth Therapeutics, Inc. (the “Issuer”)
| Item 1(b). | Address of the Issuer’s Principal Executive Offices |
The Issuer’s principal executive offices are located at:
1 Rockefeller Plaza, Suite 1039
New York, NY 10020.
| Item 2(a). | Names of Persons Filing |
This statement is filed by AIkido Pharma, Inc.
| Item 2(b). | Address of the Principal Business Office, or if none, Residence: |
One Rockefeller
Plaza, 11th Floor
New York, NY 10020
| Item 2(c). | Citizenship |
AIkido Pharma, Inc. is a Delaware corporation.
| Item 2(d). | Title of Class of Securities |
Common stock, $0.0001 par value per share.
| Item 2(e). | CUSIP Number |
44148G105
| Item 3. | If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
| Item 4. | Ownership |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identifie d in Item 1.
| (a) | Amount Beneficially Owned |
|
See Row 9 of cover page for the named Reporting Person.
| |
| (b) | Percent of Class |
|
See Row 11 of cover page for the named Reporting Person. |
3
| (c) |
Number of shares as to which such person has: | |
| (i) | sole power to vote or to direct the vote | |
|
See Row 5 of cover page for the named Reporting Person. | ||
| (ii) | shared power to vote or to direct the vote | |
|
See Row 6 of cover page for the named Reporting Person. | ||
| (iii) | sole power to dispose or to direct the disposition of | |
|
See Row 7 of cover page for the named Reporting Person. | ||
| (iv) | shared power to dispose or to direct the disposition of | |
|
See Row 8 of cover page for the named Reporting Person. | ||
| Item 5. | Ownership of Five Percent or Less of a Class |
Not Applicable.
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
Not Applicable.
| Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
Not Applicable.
| Item 8. | Identification and Classification of Members of the Group |
Not Applicable.
| Item 9. | Notice of Dissolution of Group |
Not Applicable.
| Item 10. | Certification |
Not Applicable.
4
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DATE: February 16, 2021
| AIKIDO PHARMA INC., | ||
| a Delaware corporation | ||
| By: | /s/ Anthony Hayes | |
| Name: | Anthony Hayes | |
| Title: | Chief Executive Officer | |
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations
(See 18 U.S.C. 1001)
5